CTOs on the Move

University of Maryland Medical System

www.umms.org

 
The University of Maryland Medical System (UMMS) is a university-based regional health care system focused on serving the health care needs of Maryland. We bring innovation, discovery and research to the care we provide all while educating the state`s future physicians and health care professionals through our partnership with the University of Maryland School of Medicine and the UM Schools of Nursing, Pharmacy, Social Work and Dentistry in Baltimore. As one of the largest private employers in the state, the health system`s 25,000 employees and 4,000 affiliated physicians provide primary and specialty care in more than 150 locations and at 13 hospitals. UMMS` ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.umms.org
  • 250 W. Pratt Street
    Baltimore, MD USA 21201
  • Phone: 410.328.2450

Executives

Name Title Contact Details

Similar Companies

Omnilux

Omnilux is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Public Sector Partners

Public Sector Partners, Inc. is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Informatics Outsourcing

Informatics Outsourcing is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Invitrogen Corporation

Life Technologies Corp., (NASDAQ: LIFE) www.lifetechnologies.com - On November 21, 2008, Invitrogen Corporation and Applied Biosystems Inc announced the completion of their merger transaction. Effective November 24, 2008, the two companies merged to form a new company under the name, Life Technologies Corporation

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.